Is PT-141 (Bremelanotide) Legal in Alabama? How to Access It Legally

The Short Answer: Yes, With a Valid Prescription

PT-141 (bremelanotide) is legal in Alabama when obtained through a licensed prescriber and a licensed pharmacy. The FDA approved the branded product Vyleesi in June 2019, and that approval gives bremelanotide full legal status as a prescription drug in all 50 states, including Alabama. No Alabama statute schedules or bans it beyond the standard prescription-drug requirement under Alabama Code Title 20.

What separates lawful access from unlawful access is the prescription itself. Possessing or purchasing bremelanotide without a valid prescription from a licensed provider violates both federal law (21 U.S.C. 353) and Alabama's Uniform Controlled Substances Act framework for legend drugs.

What "FDA-Approved" Actually Means for State Law

Federal approval sets the floor. Once the FDA approves a drug under 21 U.S.C. 355, states do not need separate approval statutes to permit prescribing. Alabama's Medical Practice Act (Alabama Code Section 34-24-50 et seq.) allows physicians to prescribe any FDA-approved drug within the scope of their license. That means any Alabama-licensed MD, DO, or advanced-practice provider with prescriptive authority can legally write a prescription for Vyleesi.

The FDA's June 2019 approval letter and the Vyleesi prescribing information are publicly available on the FDA website and confirm the approved indication: moderate-to-severe acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [1]

Off-Label Prescribing in Alabama

Alabama, like all states, permits off-label prescribing. A physician who determines that bremelanotide may benefit a postmenopausal woman or a male patient with sexual dysfunction can legally prescribe it based on clinical judgment. Off-label prescribing is addressed in the American Medical Association's Code of Medical Ethics and is a well-established standard across U.S. Medical practice. [2] The prescriber bears the clinical and legal responsibility for justifying the off-label use in the patient record.

Federal Framework: FDA Approval, Scheduling, and the Bulks List

Understanding the federal layer is necessary before discussing Alabama-specific rules, because federal law governs drug scheduling and compounding regardless of what any state does.

DEA Scheduling Status

Bremelanotide is not scheduled under the Controlled Substances Act. It does not appear in DEA Schedules I through V. This matters for Alabama because it means no special DEA registration is required to prescribe or dispense it, and patients do not face the criminal exposure that comes with obtaining a Schedule II or III substance without a prescription.

The FDA Bulks List and Compounding Restrictions

This is where the legal picture gets more complicated. Compounded bremelanotide (often sold as the "PT-141" peptide by research-chemical vendors) exists in a legal gray zone that is narrowing quickly.

The FDA maintains a list of bulk drug substances that may be used in compounding under Section 503A (traditional pharmacies) and Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. Bremelanotide appears on the FDA's 503B Bulks List as a Category 2 substance, meaning there are significant concerns about its use in compounding because an FDA-approved drug (Vyleesi) already exists. [3]

The FDA's own language on Category 2 substances states: "bulk drug substances that raise significant safety risks or that are essentially copies of approved drugs are not appropriate for compounding." Category 2 placement is not an outright ban, but it creates a strong presumption against routine compounding. 503A pharmacies (traditional compounding pharmacies serving individual patients) face parallel scrutiny under state pharmacy board oversight.

What This Means for "Research Chemical" PT-141

Peptide vendors selling "PT-141 for research use only" are not operating under any FDA-approved or state-licensed dispensing framework. Purchasing from these vendors does not constitute lawful access to bremelanotide in Alabama or anywhere else. The product is unregulated, purity is unverified, and the transaction lacks the prescriber-pharmacist-patient chain required by federal and Alabama law.

Alabama State Law: Pharmacy Board Rules and the Medical Practice Act

Alabama does not have a dedicated peptide-specific statute. The relevant state-level rules come from three sources: the Alabama State Board of Pharmacy, the Alabama Board of Medical Examiners, and the Alabama Uniform Controlled Substances Act.

Alabama State Board of Pharmacy

The Alabama State Board of Pharmacy (ALBOP) licenses all pharmacies that dispense to Alabama patients, including out-of-state pharmacies that ship into Alabama. [4] A compounding pharmacy filling a prescription for bremelanotide must hold an ALBOP license or a non-resident pharmacy permit. ALBOP follows USP Chapter 795 and 797 standards for compounded preparations, and its rules require that compounded drugs not be essentially copies of commercially available FDA-approved products, which aligns with the federal 503A framework.

A compounding pharmacist who produces bremelanotide injections when Vyleesi is commercially available may face ALBOP disciplinary action in addition to federal FDA scrutiny. Patients receiving compounded bremelanotide should confirm the dispensing pharmacy's licensure status directly with ALBOP.

Alabama Board of Medical Examiners

The Alabama Board of Medical Examiners (ALBME) oversees physician prescribing standards. Prescribing bremelanotide for an unapproved indication without adequate documentation, or prescribing to a patient without a valid clinical relationship, could constitute substandard care under Alabama Code Section 34-24-360. [5] Telehealth providers must establish a valid patient-provider relationship before prescribing, per Alabama's telemedicine rules adopted in 2020 following the national telehealth expansion.

Telehealth Prescribing in Alabama

Alabama allows licensed providers to prescribe via telehealth after conducting a clinically appropriate evaluation. The state does not require an in-person visit before a first prescription for non-controlled substances. Because bremelanotide is not a controlled substance, it may be prescribed via telehealth in Alabama provided the provider is licensed in Alabama (or licensed in another state with appropriate authority under the applicable compact or registration). [6]

Clinical Background: What PT-141 (Bremelanotide) Actually Does

Before seeking a prescription, patients should understand the drug's mechanism, evidence base, and who actually qualifies under the approved indication.

Mechanism of Action

Bremelanotide is a melanocortin receptor agonist. It binds primarily to MC1R and MC4R in the central nervous system. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle, bremelanotide acts centrally to modulate sexual desire pathways in the hypothalamus and limbic system. [7] This is why it is described as treating the desire deficit in HSDD rather than the mechanical components of sexual response.

Clinical Trial Evidence

The key Phase 3 program for bremelanotide consisted of two randomized, double-blind trials: RECONNECT Study 1 and RECONNECT Study 2, together enrolling 1,267 premenopausal women with HSDD. At 24 weeks, women receiving bremelanotide 1.75 mg subcutaneous reported a statistically significant increase in the number of satisfying sexual events compared to placebo (P<0.001 in both studies). The Female Sexual Function Index desire domain score improved by 0.5 points over placebo. [8] The FDA cited both studies in the Vyleesi approval package.

A 2019 paper in the Journal of Sexual Medicine by Clayton et al. Summarized the RECONNECT findings: "Bremelanotide improved sexual desire and reduced distress related to low sexual desire compared with placebo in premenopausal women with HSDD." [9]

Approved Dosing and Administration

The FDA-approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose within 24 hours, and the labeling advises no more than one dose in a 24-hour period. The prescribing information also contraindicates use in patients with cardiovascular disease because bremelanotide transiently increases blood pressure by approximately 2 to 4 mmHg and decreases heart rate. [1]

Side Effects Patients Should Know Before Requesting a Prescription

The most common adverse event in RECONNECT was nausea, affecting approximately 40% of participants. Flushing occurred in roughly 20%, and injection-site reactions in about 13%. Transient focal hyperpigmentation (darkening of the face, gums, or breasts) occurred with repeated use due to MC1R activity. Patients with darker skin tones should receive specific counseling about this risk, as the labeling notes it may be persistent. [1]

How Alabama Residents Can Access PT-141 Legally

There are two primary legal access pathways for Alabama residents.

Pathway 1: In-Person Physician Visit

An Alabama-licensed physician, nurse practitioner, or physician assistant with prescriptive authority can evaluate a patient for HSDD and write a prescription for Vyleesi. The prescription is filled at a licensed pharmacy. CVS, Walgreens, and independent pharmacies can order Vyleesi through standard wholesale channels, though stocking may vary given the relatively low volume. Patients may need to call ahead or use a specialty pharmacy.

Relevant specialists include gynecologists, sexual medicine physicians, and primary care providers trained in women's health. The International Society for the Study of Women's Sexual Health (ISSWSH) publishes clinical guidelines on HSDD diagnosis that providers may follow when evaluating patients. [10]

Pathway 2: Telehealth Prescription

Several telehealth platforms are licensed to operate in Alabama and can evaluate patients asynchronously or via video visit. Because bremelanotide is not a controlled substance, no in-person visit is federally required. The patient completes an intake form, a licensed Alabama provider reviews the clinical history, and, if appropriate, issues a prescription sent to a licensed pharmacy.

Patients should verify that any telehealth service uses providers who hold Alabama licenses and dispenses through pharmacies registered with ALBOP. Receiving medication from an unlicensed pharmacy, even via a telehealth platform, does not constitute lawful dispensing under Alabama law.

What to Bring to a Clinical Evaluation

A provider evaluating HSDD will typically use validated instruments such as the Female Sexual Distress Scale-Revised (FSDS-R) and the Female Sexual Function Index (FSFI). Patients who score above the clinical threshold for distress on the FSDS-R (a score of 11 or higher) and who meet the DSM-5 criteria for FSDD may qualify for bremelanotide. [11] Bringing a history of prior treatments, current medications (particularly antidepressants and antihypertensives, which affect sexual function), and a summary of symptom duration strengthens the evaluation and speeds the prescribing decision.

Insurance Coverage and Cost in Alabama

Vyleesi is covered by some commercial insurance plans but is not uniformly covered. Amag Pharmaceuticals (now acquired by AMAG/Nalpropion) offered a savings card program that reduces out-of-pocket cost for commercially insured patients. Medicaid in Alabama does not typically cover Vyleesi because it falls outside standard Alabama Medicaid preferred drug list categories, though providers may request prior authorization.

Without insurance, the list price for a single 1.75 mg auto-injector is approximately $1,014. Patients who use the drug infrequently (one to four times per month) may find that cost reasonable relative to specialty sexual medicine consultations; patients seeking frequent use should discuss cost-effectiveness with their provider before starting.

Generic bremelanotide is not yet available as of early 2025. The Vyleesi patent portfolio extends through the late 2020s, though patent challenges could alter that timeline.

What Is Not Legal: Common Pitfalls for Alabama Residents

Alabama residents should be aware of three common access patterns that fall outside the law.

Buying from online peptide vendors. Websites selling "PT-141 10 mg research peptide" ship a product that has not been manufactured under FDA cGMP standards, has not been reviewed by any Alabama-licensed pharmacist, and is not dispensed pursuant to a prescription. Purchasing it is a federal misdemeanor under 21 U.S.C. 331 and may constitute a violation of Alabama's Food, Drug, and Cosmetic Act (Alabama Code Title 20, Chapter 1). [12]

Compounded PT-141 from an unlicensed compounder. If a compounding pharmacy is not registered with ALBOP and does not hold a valid non-resident permit, it cannot legally ship compounded bremelanotide to an Alabama patient. The patient receives no legal protection and the product has no quality assurance.

Prescriptions issued without a valid clinical relationship. A prescription from a provider who has not conducted a clinical evaluation, or who operates a "prescription mill" that issues prescriptions for cash without assessment, may be legally invalid. Alabama pharmacists have the right and obligation to refuse to fill prescriptions that appear to lack clinical legitimacy under Alabama Code Section 34-23-1 et seq.

Physician Perspective on Appropriate Use

The ISSWSH 2019 consensus statement on HSDD notes: "The diagnosis of HSDD requires not only low desire but also personal distress about that low desire; the absence of distress makes pharmacologic treatment inappropriate." [10] This is the standard against which Alabama providers measure appropriateness.

Bremelanotide is not a drug for mild or situational low libido. Patients whose low desire is explained by relationship factors, depression being treated with SSRIs, thyroid dysfunction, or pelvic pain disorders may be better served by addressing those underlying causes before adding a melanocortin agonist.